New Delhi, Mar 18 (PTI) Drug maker Cipla on Tuesday said it has inked an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialisation of clobetasol propionate ophthalmic suspension. As per the agreement, the Mumbai-based drug maker has exclusive rights to market the innovative treatment for post-operative inflammation and pain, following ocular surgery across …